Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 2/20 | 0.50 |
| ▸ | CLK2 | P49760 | 5/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | CLK3 | P49761 | 1/20 | 0.37 |
| ▸ | MAPK7 | Q13164 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 3/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4285440 | 0.87 | OGA (0.53) | OGACLK2LRRK2GSK3BDYRK1A | |
| SCHEMBL19296123 | 0.83 | DDB1 (0.52) | OGACLK2LRRK2GSK3BDYRK1A | |
| SCHEMBL19296121 | 0.82 | OGA (0.54) | OGACLK2LRRK2GSK3BDYRK1A | |
| Hydrochloric Acid SCHEMBL19283848 | 0.82 | DDB1 (0.51) | OGACLK2LRRK2GSK3BDYRK1A | |
| SCHEMBL19283852 | 0.81 | OGA (0.53) | OGACLK2LRRK2GSK3BDYRK1A | |
| SCHEMBL23945144 | 0.80 | OGA (0.46) | OGACLK2LRRK2GSK3BDYRK1A | |
| SCHEMBL23945349 | 0.80 | OGA (0.46) | OGACLK2LRRK2GSK3BDYRK1A | |
| SCHEMBL22098019 | 0.79 | OGA (0.44) | OGACLK2LRRK2GSK3BDYRK1A | |
| Hydrochloric Acid SCHEMBL21640209 | 0.78 | OGA (0.46) | OGACLK2LRRK2GSK3BDYRK1A | |
| SCHEMBL23806650 | 0.77 | OGA (0.44) | OGACLK2LRRK2GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | OGA 839/4885CLK2 1819/4885LRRK2 606/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | OGA 839/4885CLK2 1819/4885LRRK2 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.